176 related articles for article (PubMed ID: 33229928)
1. Apolipoprotein B: the Rosetta Stone of lipidology.
Glavinovic T; Sniderman AD
Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):90-96. PubMed ID: 33229928
[TBL] [Abstract][Full Text] [Related]
2. The spectrum of type III hyperlipoproteinemia.
Sniderman AD; de Graaf J; Thanassoulis G; Tremblay AJ; Martin SS; Couture P
J Clin Lipidol; 2018; 12(6):1383-1389. PubMed ID: 30318453
[TBL] [Abstract][Full Text] [Related]
3. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.
Lorenzatti AJ; Monsalvo ML; López JAG; Wang H; Rosenson RS
Cardiovasc Diabetol; 2021 Apr; 20(1):94. PubMed ID: 33941192
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review.
Sniderman AD; Thanassoulis G; Glavinovic T; Navar AM; Pencina M; Catapano A; Ference BA
JAMA Cardiol; 2019 Dec; 4(12):1287-1295. PubMed ID: 31642874
[TBL] [Abstract][Full Text] [Related]
5. Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk.
Glavinovic T; Thanassoulis G; de Graaf J; Couture P; Hegele RA; Sniderman AD
J Am Heart Assoc; 2022 Oct; 11(20):e025858. PubMed ID: 36216435
[TBL] [Abstract][Full Text] [Related]
6. Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease?
Langlois MR; Sniderman AD
Curr Cardiol Rep; 2020 Jun; 22(8):67. PubMed ID: 32562186
[TBL] [Abstract][Full Text] [Related]
7. Phenotypes of hypertriglyceridemia caused by excess very-low-density lipoprotein.
Sniderman AD; Tremblay A; De Graaf J; Couture P
J Clin Lipidol; 2012; 6(5):427-33. PubMed ID: 23009778
[TBL] [Abstract][Full Text] [Related]
8. Identification and partial characterization of discrete apolipoprotein B containing lipoprotein particles produced by human hepatoma cell line HepG2.
Dashti N; Alaupovic P; Knight-Gibson C; Koren E
Biochemistry; 1987 Jul; 26(15):4837-46. PubMed ID: 2822101
[TBL] [Abstract][Full Text] [Related]
9. A More Atherogenic Lipoprotein Status Is Present in Adults With Type 2 Diabetes Mellitus Than in Those Without With Equivalent Degrees of Hypertriglyceridemia.
Sun CJ; Brisson D; Sharma R; Birkett N; Gaudet D; Ooi TC
Can J Diabetes; 2022 Jul; 46(5):480-486. PubMed ID: 35718690
[TBL] [Abstract][Full Text] [Related]
10. Quantifying the contribution of lipoprotein(a) to all apoB containing particles.
Chilazi M; Zheng W; Park J; Marvel FA; Khoury S; Jones SR; Martin SS
J Clin Lipidol; 2022; 16(2):220-226. PubMed ID: 35241398
[TBL] [Abstract][Full Text] [Related]
11. Sugar-Sweetened Beverage Consumption and Plasma Lipoprotein Cholesterol, Apolipoprotein, and Lipoprotein Particle Size Concentrations in US Adults.
Haslam DE; Chasman DI; Peloso GM; Herman MA; Dupuis J; Lichtenstein AH; Smith CE; Ridker PM; Jacques PF; Mora S; McKeown NM
J Nutr; 2022 Nov; 152(11):2534-2545. PubMed ID: 36774119
[TBL] [Abstract][Full Text] [Related]
12. Postprandial remnant-like lipoproteins in hypertriglyceridemia.
Ooi TC; Cousins M; Ooi DS; Steiner G; Uffelman KD; Nakajima K; Simo IE
J Clin Endocrinol Metab; 2001 Jul; 86(7):3134-42. PubMed ID: 11443178
[TBL] [Abstract][Full Text] [Related]
13. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.
Pischon T; Girman CJ; Sacks FM; Rifai N; Stampfer MJ; Rimm EB
Circulation; 2005 Nov; 112(22):3375-83. PubMed ID: 16316964
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and treatment of apolipoprotein B dyslipoproteinemias.
Sniderman A; Couture P; de Graaf J
Nat Rev Endocrinol; 2010 Jun; 6(6):335-46. PubMed ID: 20421882
[TBL] [Abstract][Full Text] [Related]
15. An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB.
Sniderman AD; Toth PP; Thanassoulis G; Furberg CD
J Clin Lipidol; 2016; 10(5):1248-58. PubMed ID: 27678443
[TBL] [Abstract][Full Text] [Related]
16. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
17. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia.
Brunzell JD; Albers JJ; Chait A; Grundy SM; Groszek E; McDonald GB
J Lipid Res; 1983 Feb; 24(2):147-55. PubMed ID: 6403642
[TBL] [Abstract][Full Text] [Related]
18. Elevated Levels of Apolipoprotein CIII Increase the Risk of Postprandial Hypertriglyceridemia.
Guan Y; Hou X; Tian P; Ren L; Tang Y; Song A; Zhao J; Gao L; Song G
Front Endocrinol (Lausanne); 2021; 12():646185. PubMed ID: 33967959
[TBL] [Abstract][Full Text] [Related]
19. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
[TBL] [Abstract][Full Text] [Related]
20. ELISA quantitation of apolipoproteins in plasma lipoprotein fractions: ApoE in ApoB-containing lipoproteins (Lp B:E) and ApoB in ApoE-containing lipoproteins (Lp E:B).
Yang CY; Xie YH; Yang M; Quion JA; Gotto AM
J Protein Chem; 1995 Oct; 14(7):503-9. PubMed ID: 8561846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
